Market Cap
$368.1M
ENTA
ENANTA PHARMACEUTICALS INC
$13.02 ▲ +1.40%
Prev close $12.84Market cap$368.1M
ConsensusStrong Buy
12-mo target$21.83 (+67.7%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)13 New Institutional Positions9 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ENTA right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$264.0M
Inst. Activity
13 buys / 9 sells
SEC Reports
1
Price chart 30d -7.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 10, 2026 SEC
Enanta reported a narrower-than-expected net loss of $0.45 per share for fiscal Q2 2026, beating the consensus estimate
8-K — Impact 7/10
Aug 10, 2026 earnings_calendar
ENTA Q3 2026 Earnings Scheduled — 2026-08-10
Aug 8, 2026 Insider
Rottinghaus Scott T. surrendered for taxes 1,467 shares
Chief Medical Officer @ $13.34 ($19.6K)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — TRIM
643,967 shares ($9.4M)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
464,649 shares ($6.8M)
Jun 23, 2026 Event
Enanta Pharmaceuticals, Inc. v. Pfizer Inc.
Court ruling from Court of Appeals for the Federal Circuit. Docket: 25-1427
Mar 11, 2026 Insider
FOLETTA MARK G was granted 20,000 shares
Director
Mar 11, 2026 Insider
Vance Terry was granted 20,000 shares
Director
Analyst ratings buy % +7.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Jun 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% |
Price targets
Where 6 covering analysts think ENTA trades over the next 12 months.
$21.83 +67.7% upside Strong Buy
Current$13.02 Low$19.00 Median$20.00 High$32.00 6 analysts
$19.00$32.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
1 SEC filing reports analyzed · 1 bullish, 0 bearish, 0 mixed, 0 neutral · avg impact 7.0/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 25, 2026
Clinical Trial
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
Phase Phase 2 — COMPLETED
Aug 10, 2026
earnings_calendar
ENTA Q3 2026 Earnings Scheduled — 2026-08-10
Jun 23, 2026
Enforcement
Enanta Pharmaceuticals, Inc. v. Pfizer Inc.
Court ruling from Court of Appeals for the Federal Circuit. Docket: 25-1427
May 11, 2026
earnings_calendar
ENTA Q2 2026 Earnings Scheduled — 2026-05-11
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.77 | $-0.95–$-0.55 | 11.5% | +0.0% | 0↑ 2↓ | $0.0B | 5 |
| Next Q | $-0.41 | $-0.48–$-0.33 | 3.6% | -11.0% | 0↑ 1↓ | $0.0B | 2 |
| Current FY | $-2.29 | $-2.49–$-2.09 | 40.3% | +0.0% | 0↑ 2↓ | $0.1B | 4 |
| Next FY | $-2.37 | $-3.08–$-1.75 | -3.6% | +0.0% | 0↑ 2↓ | $0.1B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.770 | — |
| 7d ago | $-0.770 | — |
| 30d ago | $-0.770 | — |
| 60d ago | $-0.644 | -0.126 |
| 90d ago | $-0.673 | -0.097 |
Institutional ownership
Which big funds own ENTA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $264.0M total value (18,116,757 shares) as of 2026-Q2. Top holders: Jupiter, BlackRock,, FARALLON. Net buying activity: 13 institutions added/increased vs 9 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Jupiter Topco LLC | 3,654,920 | $53.3M | 20.2% | — |
| BlackRock, Inc. | 3,244,448 | $47.3M | 17.9% | ADD +67.8% |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 2,418,202 | $35.3M | 13.4% | ADD +30.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,211,769 | $17.7M | 6.7% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,011,494 | $14.7M | 5.6% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 776,634 | $11.3M | 4.3% | — |
| MILLENNIUM MANAGEMENT LLC | 643,967 | $9.4M | 3.6% | TRIM -27.0% |
| STATE STREET CORP | 576,117 | $8.4M | 3.2% | — |
| RENAISSANCE TECHNOLOGIES LLC | 557,600 | $8.1M | 3.1% | — |
| GOLDMAN SACHS GROUP INC | 464,649 | $6.8M | 2.6% | ADD +75.3% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | TRIM | 882,097 | 643,967 | -27.0% | $9.4M |
| GOLDMAN SACHS GROUP INC | ADD | 265,088 | 464,649 | +75.3% | $6.8M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 203,252 | 282,682 | +39.1% | $4.1M |
| Rockefeller Capital Management L.P. | DOUBLED | 2,563 | 150,546 | +5773.8% | $2.2M |
| MARSHALL WACE, LLP | TRIM | 210,070 | 131,995 | -37.2% | $1.9M |
| Qube Research & Technologies Ltd | TRIM | 116,961 | 81,005 | -30.7% | $1.2M |
| SEI INVESTMENTS CO | TRIM | 109,077 | 66,685 | -38.9% | $972.3K |
| CITADEL ADVISORS LLC | NEAR_EXIT | 262,533 | 50,844 | -80.6% | $741.3K |
| Quantinno Capital Management LP | ADD | 35,122 | 45,109 | +28.4% | $657.7K |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 18,608 | 40,908 | +119.8% | $596.4K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 25 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 8, 2026 | Rottinghaus Scott T. | Chief Medical Officer | TAX W/H | 1,467 | $13.34 | $19.6K |
| Mar 11, 2026 | FOLETTA MARK G | Director | AWARD | 20,000 | — | — |
| Mar 11, 2026 | Vance Terry | Director | AWARD | 20,000 | — | — |
| Mar 11, 2026 | Russell Lesley | Director | AWARD | 20,000 | — | — |
| Mar 11, 2026 | Peterson Kristine | Director | AWARD | 20,000 | — | — |
| Mar 11, 2026 | Hata Yujiro S | Director | AWARD | 20,000 | — | — |
| Mar 11, 2026 | CARTER BRUCE L A | Director | AWARD | 20,000 | — | — |
| Feb 12, 2026 | Kowalsky Matthew Paul | Chief Legal Officer | TAX W/H | 1,902 | $14.25 | $27.1K |
| Feb 12, 2026 | Kowalsky Matthew Paul | Chief Legal Officer | AWARD | 1,318 | — | — |
| Feb 12, 2026 | Luu Brendan | Chief Business Officer | AWARD | 1,575 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ENTA.
Shares short
2,600,199
Settlement Sep 15, 2026
Change vs prior
-0.6%
Semi-monthly cycle
Days to cover
10.7
At avg daily volume
Of shares outstanding
≈8.9%
Estimate — not % of float
All ENTA filing & press-release reports (1)
- 8-K reportAug 10, 2026